NORML Releases Updated Version of Book Reviewing 450+ Cannabis-Related Studies

NORML released an updated and revised version of “Clinical Applications for Cannabis & Cannabinoids: A Review of the Recent Scientific Literature, 2000-2021.” Proceeds from the book will be used to fund NORML’s advocacy efforts.

Full story after the jump.

Cannabis advocacy organization NORML has released an updated and revised version of “Clinical Applications for Cannabis & Cannabinoids: A Review of the Recent Scientific Literature, 2000-2021,” which includes reviews of more than 450 peer-reviewed studies related to the safety and therapeutic efficacy of cannabis.

The previous version of the book was issued in 2017 and, since then, NORML says there have been “thousands of studies relevant to the medicinal properties of cannabis.”

“NORML has long advocated for the enactment of evidence-based marijuana policies. When it comes to addressing questions specific to the safety and therapeutic efficacy of cannabis, this publication provides the evidence that patients and their physicians as well as lawmakers need to know.” NORML Deputy Director Paul Armentano, the book’s chief author, in a statement

The book is currently listed as the top new release in the medical research category on Amazon, where it is available for the Kindle for $5.99. Proceeds from the book are used to fund NORML’s advocacy efforts directly.

In 2020, NORML notes, researchers worldwide published a record 3,500-plus scientific papers on cannabis, according to data compiled by the National Library of Medicine and PubMed.gov. So far this year, there have been over 3,600 papers published on the topic and, in all, PubMed now cites over 38,000 scientific papers on cannabis, the organization said in a press release.

A soft-cover version of the book is also available for pre-order on the NORML website for $12.00.

Get daily cannabis business news updates. Subscribe

Have an additional perspective to share? Send us a message to let us know, and if your comment is chosen by our editors it could be featured here.

End


Ganjapreneur is made possible by our partners:

Latest Cannabis News

View all news Get email updates

Featured Business Profiles

Create a profile View all categories

From Our Partners